Recently, targeting immune checkpoint mediated by programmed cell death protein 1 (PD-1) or its ligand PD-L1 achieves promising clinical response in numerous clinical studies, which opened a new era of NSCLC therapy [2–4]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.